A "game-changer" jab to treat opioid dependence could ease pressure on health care services, outperforming other standard treatments, a new report involving University of Hertfordshire academics ...
Phase 3 post-hoc analysis indicates less fentanyl and overall illicit opioid use for weekly/monthly buprenorphine depots versus daily standard treatment in a difficult to treat patient population LUND ...
LUND, Sweden, Nov. 26, 2019 /PRNewswire/ -- Camurus announced today topline results from the 24-week, randomized, controlled, open-label, DEBUT study of weekly and monthly Buvidal® (prolonged-release ...
Camurus, a Swedish research-based pharmaceutical company, announced that the European Commission (EC) has approved weekly and monthly Buvidal (prolonged release buprenorphine) for the treatment of ...
To overcome problematic opioid use, traditional forms of opioid substitution therapy, such as methadone and oral buprenorphine, have become valuable tools. Research shows that patients receiving ...
The full CMI on the next page has more details. If you are worried about being given this medicine, speak to your doctor, nurse practitioner or pharmacist. Buvidal contains the active ingredient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results